199 related articles for article (PubMed ID: 23933266)
1. Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors.
Barbier L; Garcia S; Cros J; Borentain P; Botta-Fridlund D; Paradis V; Le Treut YP; Hardwigsen J
J Hepatol; 2013 Dec; 59(6):1223-30. PubMed ID: 23933266
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients.
Walsh C; Barkun J; Tchervenkov J; Deschenes M; Ghali P; Wong P; Chaudhury P; Paraskevas S; Metrakos P; Cantarovich M
Transplantation; 2013 Feb; 95(3):495-500. PubMed ID: 23296149
[TBL] [Abstract][Full Text] [Related]
3. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
[TBL] [Abstract][Full Text] [Related]
4. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
7. [Sirolimus use in heart transplantation recipients with chronic renal dysfunction].
Yin D; Huang J; Feng L; Liao ZK; Feng GX; Wang W; Song YH; Hu SS
Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):136-40. PubMed ID: 22490714
[TBL] [Abstract][Full Text] [Related]
8. Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients.
Manzia TM; Angelico R; Ciano P; Mugweru J; Owusu K; Sforza D; Toti L; Tisone G
World J Gastroenterol; 2014 Sep; 20(34):12217-25. PubMed ID: 25232255
[TBL] [Abstract][Full Text] [Related]
9. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
11. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
[TBL] [Abstract][Full Text] [Related]
12. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
13. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function.
Weir MR; Blahut S; Drachenburg C; Young C; Papademitriou J; Klassen DK; Cangro CB; Bartlett ST; Fink JC
Am J Nephrol; 2004; 24(4):379-86. PubMed ID: 15237243
[TBL] [Abstract][Full Text] [Related]
14. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
[TBL] [Abstract][Full Text] [Related]
15. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
16. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
[TBL] [Abstract][Full Text] [Related]
17. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
Bajjoka I; Hsaiky L; Brown K; Abouljoud M
Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
[TBL] [Abstract][Full Text] [Related]
18. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
19. Intracellular ATP production in CD4+ T cells as a predictor for infection and allograft rejection in trough-level guided pediatric liver transplant recipients under calcineurin-inhibitor therapy.
Schulz-Juergensen S; Burdelski MM; Oellerich M; Brandhorst G
Ther Drug Monit; 2012 Feb; 34(1):4-10. PubMed ID: 22210096
[TBL] [Abstract][Full Text] [Related]
20. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
